MeSH tree: C20.111.590
Systemic lupus erythematosus (SLE) is a complex and potentially life-threatening autoimmune disease. Part of the complexity stems from how it can differ from person to person—giving rise to marked heterogeneity in not only ...
Aug 25, 2025
0
11
In lupus nephritis, attainment of complete renal response (CRR)/partial renal response (PRR) and lupus low disease activity state (LLDAS) is associated with best relapse-free survival, with independent associations seen with ...
Aug 14, 2025
0
25
In a comprehensive study, researchers from the Department of Epidemiology at the Faculty of Medicine at the University of Augsburg have provided reliable evidence for a link between chronic inflammatory diseases and the development ...
Aug 12, 2025
0
24
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with a spectrum of very different manifestations and variable severity.
Aug 8, 2025
0
18
New research published in Nature has uncovered powerful evidence that may explain why a new chemical modification of RNA is made in cells.
Aug 6, 2025
0
50
At the time when patients with lupus, or systemic lupus erythematosus (SLE), are diagnosed, approximately 15% to 30% will already have the inflammation-caused kidney disease lupus nephritis, which compromises kidney function ...
Aug 5, 2025
0
14
UCSF researchers have found that certain antiviral genes become less active over time in lupus, revealing why some patients see their symptoms fade as they age.
Jul 29, 2025
0
65
Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, has joined with 40 other centers in the U.S. and Europe as a site in one of the first clinical trials testing cellular therapy ...
Jul 25, 2025
0
20
Hispanic people have an increased risk of peripheral neuropathy compared to white people that cannot be explained by many health, lifestyle and social risk factors, according to a study published in Neurology.
Jul 16, 2025
0
11
The U.S. Food and Drug Administration has approved GSK's autoinjector of Benlysta (belimumab) for subcutaneous injection in patients ≥5 years of age with active lupus nephritis who are receiving standard therapy.
Jul 1, 2025
0
17
